Skip to main content

Table 1 Infant characteristics overall and by infants’ intervention groups

From: Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial

 

ISTi (10 clusters)

PCDi (11 clusters)

Total

N = 313

N = 444

N = 757

Birthweight (grams)a

3045 (2780, 3330)

3020 (2770, 3320)

3030 (2770, 3320)

Low birth weight (< 2500 g)b

29/286 (10%)

37/401 (9.2%)

66/687 (9.6%)

Birthweight > 3500 gb

40/286 (14%)

55/401 (14%)

95/687 (14%)

Infant sex (female)b

147/313 (47%)

219/444 (49%)

366/757 (48%)

Foetal Hb and anaemia

 Foetal (cord) Hb (g/dL)a

14.7 (3.3)

14.7 (3.0)

14.7 (3.2)

 Foetal (cord) Hb < 10 g/dLb

24/271 (8.9%)

26/381 (6.8%)

50/652 (7.7%)

 Foetal (cord) Hb < 7 g/dLb

7/271 (2.6%)

3/381 (0.8%)

10/652 (1.5%)

Cord malaria by microscopy

 P. falciparumb

1/211 (0.5%)

1/322 (0.3%)

2/533 (0.4%)

 P. vivaxb

0/211 (0.0%)

0/322 (0.0%)

0/533 (0.0%)

Cord malaria by PCR

 P. falciparumb

2/272 (0.7%)

10/381 (2.6%)

12/653 (1.8%)

 P. vivaxb

2/272 (0.7%)

10/381 (2.6%)

12/653 (1.8%)

Cord malaria (microscopy or PCR)b

4/272 (1.5%)

13/381 (3.4%)

17/653 (2.6%)

 P. falciparumb

3/273 (1.1%)

11/381 (2.9%)

14/654 (2.1%)

 P. vivaxb

2/273 (0.7%)

10/381 (2.6%)

12/654 (1.8%)

  1. ISTi intermittent screening and treatment in infants, PCDii passive case detection in infants
  2. aContinuous data are presented as median (25th percentile, 75th percentile) or mean (SD)
  3. bCategorical data are presented as frequency in valid cases (%)